A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy
The purpose of this study is to evaluate if BGB-290, an investigational cancer drug, can increase the time period that your cancer responds to treatment and does not progress (worsen). Another purpose is to evaluate if BGB-290 increases a person’s life span.
Advanced or Metastatic Gastric Cancer
-Age ≥ 18 years.
-Histologically confirmed inoperable locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction.
-Received platinum based first line chemotherapy for ≤ 28 weeks.
-Confirmed partial response (PR) maintained for ≥ 4 weeks or complete response (CR).
18 - 100
Healthy Volunteers Needed
Duration of Participation
You will receive the study drug for as long as your cancer does not get worse or you do not have bad side effects. After you finish study drug the investigator and/or study team will continue to watch you for side effects and follow your condition either with follow-up clinic visits or follow-up phone calls for the rest of your life.
Knight Cancer Institute Clinical Trials